Q4 2023
Released Jan 30, 2024, before the open
10-K filed Feb 22, 2024, 53 days after period end · 0000078003-24-000039
Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$5.93B$5.93B derived−62.4% vs Q4 2022−56.0% vs Q3 2023
Net Income-$3.37B-$3.37B derivedN/M vs Q4 2022N/M vs Q3 2023
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Cash Flowderived$5,240,000,000−38.9%
Free Cash Flowderived$4,196,000,000−44.7%
Margins · derived
Net margin-56.8%−88.5 pt vs Q4 2022
What the release said
The release
Same quarter
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures |
|---|---|---|---|---|
| Revenue | $5.93B | $15.75B | $16.19B | $11.43B |
| Net Income | -$3.37B | $4.99B | $3.39B | $846.00M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pfizer Inc · CIK 78003 · Engraved from SEC EDGAR